<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522259</url>
  </required_header>
  <id_info>
    <org_study_id>UVCMBS003</org_study_id>
    <nct_id>NCT03522259</nct_id>
  </id_info>
  <brief_title>Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery</brief_title>
  <acronym>BARIVA</acronym>
  <official_title>BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese
      patients undergoing bariatric surgery.

      The objectives are to assess the safety and feasibility of venous thromboembolism (VTE)
      prophylaxis and lung embolism with Rivaroxaban 10mg as an oral anticoagulant. After bariatric
      surgery patients receive the study medication Xarelto 10mg QD for 7, resp. 28 days.

      All clinically thromboembolic events will be assessed by ultrasound or CT, respectively, as
      soon as apparent. In addition, patients are screened for VTE at day 28 by ultrasound to
      detect clinically inapparent thromboses.

      In a subgroup of study patients (patients from the University Hospital Inselspital, Bern)
      PK/PD parameters are assessed following the last intake of rivaroxaban at day 28.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese
      patients undergoing bariatric surgery.

      Rivaroxaban as an oral anticoagulant could be an attractive option for thromboprophylaxis
      compared to subcutaneous standard treatment after bariatric surgery. Especially in high-risk
      patients where an extended duration of thromboprophylaxis after hospital discharge is
      recommended, an oral therapy would be desirable.

      The objectives are to assess the safety and feasibility of VTE prophylaxis and lung embolism
      with Rivaroxaban 10mg as an oral anticoagulant. Especially in high-risk patients where an
      extended duration of thromboprophylaxis after hospital discharge is recommended, an oral
      therapy would be desirable.

      After bariatric surgery patients receive the study medication Xarelto 10mg QD for 7, resp. 28
      days.

      In a subgroup of study patients (patients from the University Hospital Inselspital, Bern)
      PK/PD parameters are assessed following the last intake of rivaroxaban at day 28.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with symptomatic or asymptomatic VTE</measure>
    <time_frame>28 days</time_frame>
    <description>Assessed by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with symptomatic VTE within 28 days after bariatric surgery</measure>
    <time_frame>28 days</time_frame>
    <description>Assessed by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with asymptomatic VTE within 28 days after bariatric surgery</measure>
    <time_frame>28 days</time_frame>
    <description>Assessed by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality within 28 days after bariatric surgery</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>A: Rivaroxaban short arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Rivaroxaban long arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 MG Oral Tablet [Xarelto]</intervention_name>
    <description>Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)</description>
    <arm_group_label>A: Rivaroxaban short arm</arm_group_label>
    <arm_group_label>B: Rivaroxaban long arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with scheduled elective bariatric surgery or redo surgery after bariatric
             interventions

          -  Written informed consent

        Exclusion Criteria:

          -  DVT and/or PE in the patient history

          -  Myocardial infarction, transient ischemic attack or stroke within 6 months of study
             entry

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Stirnimann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Berne, University Hospital, University of Berne, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guido Stirnimann, MD</last_name>
    <phone>+41 31 632 21 11</phone>
    <phone_ext>+41316322111</phone_ext>
    <email>guido.stirnimann@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Nocito</last_name>
      <phone>+41564863002</phone>
      <email>antonio.nocito@ksb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Inselspital Berne</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Stirnimann, MD</last_name>
      <phone>+41316322111</phone>
      <email>guido.stirnimann@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic Beau-Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg Zehetner</last_name>
      <phone>+41313126112</phone>
      <email>joerg.zehetner@hirslanden.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rivaroxaban</keyword>
  <keyword>Thromboembolic prophylaxis</keyword>
  <keyword>Venous thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

